96 related articles for article (PubMed ID: 9551884)
1. A critical, invariant chain-independent role for H2-M in antigen presentation.
Swier K; Brown DR; Bird JJ; Martin WD; Van Kaer L; Reiner SL
J Immunol; 1998 Jan; 160(2):540-4. PubMed ID: 9551884
[TBL] [Abstract][Full Text] [Related]
2. Detection of aberrant association of DM with MHC class II subunits in the absence of invariant chain.
Neumann J; König A; Koch N
Int Immunol; 2007 Jan; 19(1):31-9. PubMed ID: 17105964
[TBL] [Abstract][Full Text] [Related]
3. BALB/c invariant chain mutant mice display relatively efficient maturation of CD4+ T cells in the periphery and secondary proliferative responses elicited upon peptide challenge.
Kenty G; Bikoff EK
J Immunol; 1999 Jul; 163(1):232-41. PubMed ID: 10384121
[TBL] [Abstract][Full Text] [Related]
4. Downmodulation of antigen presentation by H2-O in B cell lines and primary B lymphocytes.
Brocke P; Armandola E; Garbi N; Hämmerling GJ
Eur J Immunol; 2003 Feb; 33(2):411-21. PubMed ID: 12645938
[TBL] [Abstract][Full Text] [Related]
5. The MHC class II-associated invariant chain: a molecule with multiple roles in MHC class II biosynthesis and antigen presentation to CD4+ T cells.
Bertolino P; Rabourdin-Combe C
Crit Rev Immunol; 1996; 16(4):359-79. PubMed ID: 8954255
[TBL] [Abstract][Full Text] [Related]
6. An essential role for HLA-DM in antigen presentation by class II major histocompatibility molecules.
Morris P; Shaman J; Attaya M; Amaya M; Goodman S; Bergman C; Monaco JJ; Mellins E
Nature; 1994 Apr; 368(6471):551-4. PubMed ID: 8139689
[TBL] [Abstract][Full Text] [Related]
7. MHC class II antigen presentation pathway in murine tumours: tumour evasion from immunosurveillance?
Walter W; Lingnau K; Schmitt E; Loos M; Maeurer MJ
Br J Cancer; 2000 Nov; 83(9):1192-201. PubMed ID: 11027433
[TBL] [Abstract][Full Text] [Related]
8. Unexpected reactivities of T cells selected by a single MHC-peptide ligand.
Singh N; Van Kaer L
J Immunol; 1999 Oct; 163(7):3583-91. PubMed ID: 10490950
[TBL] [Abstract][Full Text] [Related]
9. Comparison of Abeta(b-/-), H2-DM(-), and CIITA(-/-) in second-set skin allograft rejection.
Felix NJ; de Serres S; Meyer AA; Ting JP
J Surg Res; 2002 Feb; 102(2):185-92. PubMed ID: 11796017
[TBL] [Abstract][Full Text] [Related]
10. Engagement of B cell receptor regulates the invariant chain-dependent MHC class II presentation pathway.
Zimmermann VS; Rovere P; Trucy J; Serre K; Machy P; Forquet F; Leserman L; Davoust J
J Immunol; 1999 Mar; 162(5):2495-502. PubMed ID: 10072488
[TBL] [Abstract][Full Text] [Related]
11. Distinct peptide loading pathways for MHC class II molecules associated with alternative Ii chain isoforms.
Bikoff EK; Kenty G; Van Kaer L
J Immunol; 1998 Apr; 160(7):3101-10. PubMed ID: 9531264
[TBL] [Abstract][Full Text] [Related]
12. Leishmania major infection in major histocompatibility complex class II-deficient mice: CD8+ T cells do not mediate a protective immune response.
Erb K; Blank C; Ritter U; Bluethmann H; Moll H
Immunobiology; 1996 Jul; 195(2):243-60. PubMed ID: 8877400
[TBL] [Abstract][Full Text] [Related]
13. Identification of residues in the class II-associated Ii peptide (CLIP) region of invariant chain that affect efficiency of MHC class II-mediated antigen presentation in an allele-dependent manner.
Gautam AM; Yang M; Milburn PJ; Baker R; Bhatnagar A; McCluskey J; Boston T
J Immunol; 1997 Sep; 159(6):2782-8. PubMed ID: 9300699
[TBL] [Abstract][Full Text] [Related]
14. Pepstatin A-sensitive aspartic proteases in lysosome are involved in degradation of the invariant chain and antigen-processing in antigen presenting cells of mice infected with Leishmania major.
Zhang T; Maekawa Y; Yasutomo K; Ishikawa H; Fawzy Nashed B; Dainichi T; Hisaeda H; Sakai T; Kasai M; Mizuochi T; Asao T; Katunuma N; Himeno K
Biochem Biophys Res Commun; 2000 Sep; 276(2):693-701. PubMed ID: 11027533
[TBL] [Abstract][Full Text] [Related]
15. Detection of aberrant transcription of major histocompatibility complex class II antigen presentation genes in chronic lymphocytic leukaemia identifies HLA-DOA mRNA as a prognostic factor for survival.
Souwer Y; Chamuleau ME; van de Loosdrecht AA; Tolosa E; Jorritsma T; Muris JJ; Dinnissen-van Poppel MJ; Snel SN; van de Corput L; Ossenkoppele GJ; Meijer CJ; Neefjes JJ; Marieke van Ham S
Br J Haematol; 2009 May; 145(3):334-43. PubMed ID: 19245431
[TBL] [Abstract][Full Text] [Related]
16. Polarized transport of MHC class II molecules in Madin-Darby canine kidney cells is directed by a leucine-based signal in the cytoplasmic tail of the beta-chain.
Simonsen A; Pedersen KW; Nordeng TW; von der Lippe A; Stang E; Long EO; Bakke O
J Immunol; 1999 Sep; 163(5):2540-8. PubMed ID: 10452991
[TBL] [Abstract][Full Text] [Related]
17. Quality control of MHC class II associated peptides by HLA-DM/H2-M.
Vogt AB; Arndt SO; Hämmerling GJ; Kropshofer H
Semin Immunol; 1999 Dec; 11(6):391-403. PubMed ID: 10625593
[TBL] [Abstract][Full Text] [Related]
18. Mutation of the invariant chain transmembrane region inhibits II degradation, prolongs association with MHC class II, and selectively disrupts antigen presentation.
Frauwirth K; Shastri N
Cell Immunol; 2001 May; 209(2):97-108. PubMed ID: 11446742
[TBL] [Abstract][Full Text] [Related]
19. BCL-6-deficient mice reveal an IL-4-independent, STAT6-dependent pathway that controls susceptibility to infection by Leishmania major.
Dent AL; Doherty TM; Paul WE; Sher A; Staudt LM
J Immunol; 1999 Aug; 163(4):2098-103. PubMed ID: 10438949
[TBL] [Abstract][Full Text] [Related]
20. Invariant chain induces B cell maturation in a process that is independent of its chaperonic activity.
Matza D; Lantner F; Bogoch Y; Flaishon L; Hershkoviz R; Shachar I
Proc Natl Acad Sci U S A; 2002 Mar; 99(5):3018-23. PubMed ID: 11867743
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
